Ning Ding

Prof. Ning Ding


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2014 in ACS Nano
Verified
Journal Article
Closed access
KSKun Shao
Kun Shao
NDNing Ding
Ning Ding
SHShixian Huang
Shixian Huang
SRSumei Ren
Sumei Ren
YZYu Zhang
Yu Zhang
CJChen Jiang
Chen Jiang

18 June 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GSGaopeng Song
Gaopeng Song
SYSen Yang
Sen Yang
WZWei Zhang
Wei Zhang
YCYingli Cao
Yingli Cao
PWPeng Wang
Peng Wang
YLYingxia Li
Yingxia Li

13 August 2014 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
KSKun Shao
Kun Shao
YZYu Zhang
Yu Zhang
NDNing Ding
Ning Ding
SHShixian Huang
Shixian Huang
JWJiqin Wu
Jiqin Wu
JCJianjun Cheng
Jianjun Cheng

20 February 2017 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
DYDongming Yao
Dongming Yao
YLYichu Liu
Yichu Liu
SYShiqiang Yan
Shiqiang Yan
YLYingxia Li
Yingxia Li
CHChun Hu
Chun Hu
NDNing Ding
Ning Ding
Although there are numerous claims of remote group participation leading to the synthesis of the expected glycosides with improved anomeric geometry outcome in glycosylation, there is still a lack of enough strong evidence and this has led to a long-term debate, particularly for equatorial 4-O group participation. In this work, we were able to synthesize and isolate a stable seven-membered trichlorooxazepine ring bridging intermediate with a high yield by employing a 2-azido-2-deoxy-glucopyranosyl donor, which provides strong evidence to support the putative participation of the equatorial 4-O group in glycosylation.

22 August 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JWJuan Wang
Juan Wang
YPYuanqiu Peng
Yuanqiu Peng
YLYuan Liu
Yuan Liu
JYJun Yang
Jun Yang
NDNing Ding
Ning Ding
WTWenfu Tan
Wenfu Tan
Berberine (BBR), a natural alkaloid compound, is used as a non-prescription drug in China for treating diarrhea and gastroenteritis. Many studies have revealed that BBR possesses anticancer effect. However, the molecular mechanisms underlying its anticancer action is far from being fully elucidated. This study is aimed to determine the effect of BBR on the hedgehog (Hh) activity and the growth of cancers addiction to Hh activity. The Hh activity was determined by dual luciferase assays and quantitative RT-PCR analyses. The growth inhibition of BBR on medulloblastoma which was obtained from ptch+/−;p53−/− mice was analyzed by 5-bromo-2-deoxyuridine (Brdu) assays and by allografting the medulloblastoma into nude mice. The data were statistically analyzed by one-way analysis of variance (ANOVA), and multiple comparison between the groups was performed using Dunnett’s method. In this study, we found that BBR significantly inhibited the Hh pathway activity. Meanwhile, we observed that BBR failed to affect the transcriptional factors activities provoked by tumor necrosis factor-α (TNF-α) and Prostaglandin E2 (PGE2), thus suggesting its unique property against Hh pathway activity. Further studies revealed that BBR inhibited the Hh pathway activity by potentially targeting the critical component Smoothened (Smo) and most likely shared the same binding site on Smo with cyclopamine, a classical Smo inhibitor. Finally, we demonstrated that BBR obviously suppressed the Hh-dependent medulloblastoma growth in vitro and in vivo. Collectively, our study uncovered a novel molecular mechanism responsible for the anticancer action of BBR, thus opening the way for the usage of BBR for therapeutics of cancers addiction to aberrant Hh pathway activity.

1 July 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NDNing Ding
Ning Ding
QCQing Chen
Qing Chen
WZWei Zhang
Wei Zhang
SRSumei Ren
Sumei Ren
YGYing Guo
Ying Guo
YLYingxia Li
Yingxia Li